KPTI Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class drugs directed against nuclear transport and related targets to treat cancer and other diseases.

$4.61  -0.42 (-8.35%)
As of 06/28/2022 13:36:59 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  11/06/2013
Outstanding shares:  79,418,349
Average volume:  2,615,677
Market cap:   $410,592,864
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BG3FZW0
Valuation   (See tab for details)
PE ratio:   -3.80
PB ratio:   7.56
PS ratio:   1.75
Return on equity:   130.08%
Net income %:   -46.14%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy